Figure 7.

Tumor imaging with ¹¹¹In-DOTA(GSG)-KCCYSL peptide. MDA-MB-435 breast tumor–xenografted SCID mice were injected in the tail vein with 11.1 MBq of ¹¹¹In-DOTA(GSG)-KCCYSL or ¹¹¹In-DOTA(GSG)-KYLCSC scrambled peptide and imaged in a microSPECT scanner. The SPECT images were fused with conventional microCT images to validate regions of increased radiolabeled ligand uptake. A, coregistered microSPECT/CT radioligand uptake image with ¹¹¹In-DOTA(GSG)-KYLCSC; B, coregistered microSPECT/CT image with ¹¹¹In-DOTA(GSG)-KCCYSL; C, microSPECT/CT image axial view focusing on tumor uptake of the radioligand. D, in vivo blocking studies with ¹¹¹In-DOTA(GSG)-KCCYSL in MDA-MB-435 breast tumor–xenografted SCID mice. Fifteen minutes after injection of the nonradiolabeled In-DOTA(GSG)-KCCYSL (10–5-10–12 mol/L) peptide, 0.11 MBq of radiolabeled counterpart was injected and the blocking efficiency was evaluated after 2 h. A 50% block of the radiolabeled peptide binding to the tumor tissue was observed. Columns, mean of three animals for each experiment; bars, SD. *, P < 0.001. Reprinted with permission from reference number ⁵⁵ (Figure 5), Copyright 2007 American Association for Cancer Research, Inc.